Search Results for “EC” – Page 240 – media

invoX Pharma’s FS222 delivers encouraging solid tumour treatment results

invoX Pharma Limited has presented updated findings from its phase 1 study of FS222, showcasing significant anti-tumour activity in patients with advanced solid tumours. The data, revealed at the 2024 American Society of Clinical Oncology Annual Meeting, highlights FS222’s potential as a ground-breaking treatment option. FS222, a CD137/PD-L1 bispecific antibody, is part of invoX’s innovative product pipeline. The phase 1 trial involved 100 subjects and aimed to establish the drug’s safety and maximum tolerated dose. The study also assessed FS222’s anti-tumour activity, pharmacokinetics, and pharmacodynamics. The treatment, administered every four weeks, led to increased T cell proliferation and CD8+ T cell infiltration within tumours. While treatment-related adverse events were dose-dependent, they remained manageable and reversible. Dr Elena Garralda, Director of Early Drug Development at Vall d’Hebron University Hospital, commented on the drug’s potential: “While there have been great advances in immuno-oncology research, existing treatments continue to face challenges with response ...
- Source: drugdu
- 61
- June 6, 2024
EpiEndo and AlveoliX achieve milestone in ulcerative colitis treatment

EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company, and AlveoliX, an innovator in organ-on-chip technology, have announced significant advancements in their joint project, the EpicoliX Project, to develop a novel treatment for ulcerative colitis (UC). Supported by Eurostars, the Icelandic Technology Development Fund, and Innosuisse, the project has identified Enterothelin, a Barriolide compound, as a lead candidate for a first-in-class therapy. UC is a debilitating inflammatory bowel disease affecting a significant portion of the global population. The EpicoliX Project, which began in May 2021, leverages AlveoliX’s organ-on-chip technology and EpiEndo’s expertise in chronic inflammatory diseases to meet the urgent need for effective UC treatments. The project’s key achievements include the development of a new gut-on-chip model that simulates the colon epithelium of UC patients. This model has been crucial in screening EpiEndo’s drug libraries and selecting Enterothelin as the lead candidate. The compound has undergone extensive preclinical testing, including in vivo studies, ...
- Source: drugdu
- 61
- June 6, 2024
DNA Spit Test More Accurate At Identifying Future Prostate Cancer Risk

Currently, the prostate-specific antigen (PSA) test is widely used to identify men who are at an increased risk of prostate cancer based on factors like age and ethnicity, as well as those showing symptoms. Elevated PSA levels may indicate prostate cancer, prompting further investigations such as MRI scans, biopsies, and treatments. However, the PSA test often results in false positives—incorrectly indicating prostate cancer in three out of four instances. It also detects cancers that grow so slowly they are unlikely to pose a significant health threat, leading to potentially unnecessary medical procedures. Now, a saliva-based test that individuals can perform at home has proven better at predicting the risk of developing prostate cancer than the traditional blood test. Researchers from The Institute of Cancer Research (London, UK) and The Royal Marsden NHS Foundation Trust (London, UK) conducted a trial of this innovative DNA test that screens for genetic variants associated ...
- Source: drugdu
- 88
- June 5, 2024
Virtual Therapeutics, Akili Interactive Strike Definitive Merger Agreement Seeking to Improve Mental Health Through Immersive Video Games

Don Tracy, Associate Editor Under terms of the deal, Akili will become a wholly owned subsidiary of Virtual Therapeutics, with Akili shareholders receiving $0.4340 per share of common stock in cash.Virtual Therapeutics and Akili, Inc. announced that they have agreed to terms on a definitive merger agreement, aiming to establish a digital health company that creates engaging and immersive games to improve mental health. Under terms of the merger, Akili will now work as a wholly owned company of Virtual Therapeutics, Akili shareholders will receive $0.4340 per share of common stock in cash, representing a 4% premium to the closing stock price.1 “In today’s global mental health crisis, patients deserve access to clinically validated solutions that address their specific needs. We have been able to advance multiple solutions on our platform since founding Virtual Therapeutics, and we look forward to taking a significant step forward through this merger,” said Dan ...
- Source: drugdu
- 93
- June 5, 2024
New UCL-developed immunotherapy shows promising results in treating bone cancer

Bone cancer affects more than 150,000 people in the UK and is often resistant to chemotherapy A new type of immunotherapy developed by researchers from University College London (UCL) has demonstrated promising preclinical results in treating bone cancer. Published in Science Translational Medicine, the OPS-gdT treatment platform outperformed conventional immunotherapy when controlling the growth of osteosarcoma, a form of bone cancer. Affecting more than 150,000 people in the UK, cancer that begins or spreads to the bones is hard to treat as it is frequently resistant to chemotherapy and is the leading cause of cancer-related death. Researchers used a small subset of immune cells known as gamma-delta T (gdT) cells, a type of immune cell that can be made from healthy donor immune cells, to provide an efficient and cost-effective solution for treating this condition. gdT cells work to kill antibody-labelled targets safely from person to person without risking graft-versus-host ...
- Source: drugdu
- 70
- June 5, 2024
Novartis Pivotal Phase III ASC4FIRST Study Provides Efficacy and Safety Data for Scemblix in Newly Diagnosed CML Patients

Novartis recently presented positive results from the pivotal Phase III ASC4FIRST study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting: the treatment of patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) with Scemblix® at Week 48 demonstrated greater efficacy and safety than the investigator’s choice of tyrosine kinase inhibitors (TKIs) (imatibe Scemblix demonstrated a superior major molecular response (MMR) rate at week 48 than both investigator-selected tyrosine kinase inhibitors (TKIs) (imatinib, nilotinib, dasatinib, and bosutinib) and imatinib alone.Scemblix demonstrated a higher MMR rate at week 48 than the second-generation TKIs (nilotinib, dasatinib, and bosutinib) with higher rate values.The MMR rate was higher than that of the second-generation TKIs. In addition, Scemblix demonstrated a favorable safety and tolerability profile, with fewer adverse events (AEs) and treatment interruptions relative to imatinib and second-generation TKIs. Tim Hughes, M.D., professor at the South Australian ...
- Source: drugdu
- 94
- June 5, 2024
GSK’s Quest to Bring Myeloma Drug Back to the Market Stops for a Data Drop at ASCO

GSK’s Blenrep has pivotal clinical trial results showing the multiple myeloma therapy reduced the risk of disease progression or death by nearly 50%. The results were presented Sunday during the annual meeting of the America Society of Clinical Oncology.A GSK multiple myeloma drug that was withdrawn from the market is accumulating new clinical data that could support its return — perhaps as an earlier line of therapy. With the latest results, clinicians and GSK executives say they may have figured out how to address a lingering question about how to safely dose the drug, Blenrep. The new data were presented Sunday during the annual meeting of the American Society of Clinical Oncology in Chicago. Blenrep is an antibody drug conjugate (ADC) that targets the BCMA protein on multiple myeloma cells, delivering to them a payload of toxic chemotherapy. There are many multiple myeloma drugs available, but frequent relapse in this ...
- Source: drugdu
- 109
- June 4, 2024
EMA endorses AbbVie’s Skyrizi for ulcerative colitis

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has granted AbbVie’s ulcerative colitis (UC) drug Skyrizi (risankizumab) a positive recommendation for approval. The committee’s recommendation was based on results from two Phase III studies. In the INSPIRE trial (NCT03398148), 20.3% of patients in the Skyrizi treatment group achieved clinical remission, compared to 6.2% in the placebo group. Furthermore, in the Phase III COMMAND study (NCT03398135), 51% of patients treated with Skyrizi 180 mg and 48% of patients treated with Skyrizi 360mg demonstrated endoscopic improvement in week 52. Skyrizi is a monoclonal antibody therapy that inhibits interleukin-23 (IL-23). This reduces anti-inflammatory processes. In the 31 May press release, Dr Edouard Louis, the head of gastroenterology at University Hospital CHU of Liège Belgium said: “These results suggest that risankizumab may help patients coping with the challenging symptoms of ulcerative colitis, which include abdominal pain, bowel urgency and ...
- Source: drugdu
- 109
- June 4, 2024
NHS platform announced to accelerate personalised cancer vaccine clinical trials

The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines The NHS has announced that it has treated its first patient in England with a personalised cancer vaccine in a clinical trial as part of NHS England’s new Cancer Vaccine Launch Pad (CVLP). Following the launch of the trial, thousands of cancer patients in England are set to be fast-tracked to access personalised cancer vaccines to help find new life-saving treatments. In partnership with Genomics England, the NHS CVLP will help speed up access to mRNA-personalised cancer vaccine clinical trials for cancer patients while accelerating the development of cancer vaccines as a form of treatment. With 30 hospitals in England already signed up to participate, the scheme intends to collaborate with the pharmaceutical industry to include patients across many cancer types. Taking place in several NHS trusts across the country to treat different types of ...
- Source: drugdu
- 72
- June 4, 2024
The Crick announces new partnerships with SMEs and MRC for research

The projects will focus on a range of research areas, including Down’s syndrome and ALS The Francis Crick Institute has announced six new partnerships with small and medium-sized enterprises (SMEs) with support from the Medical Research Council (MRC) focused on innovative discovery projects led by Crick researchers. Supported by an MRC Business Engagement Fund Award, as part of UK Research and Innovation, the collaborations will focus on the application of novel cutting-edge technologies, encompassing a diverse range of research to deliver impactful outcomes. Paul Mercer, head of collaboration, the Crick, commented: “We are… excited to be able to develop these research partnerships with SMEs, diversifying the opportunity for development of Crick discoveries through the application of disruptive innovations.” Partners include Perha Pharmaceuticals, Scalable Minds, Broken String Biosciences, Hertility Health, Automata Technologies and Mytos. The projects will focus on a range of research, including pharmacological treatments for congenital heart defects in ...
- Source: drugdu
- 85
- June 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.